{"id":"h-pylori-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Gastrointestinal symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The H. pylori vaccine works by presenting bacterial antigens to the immune system, triggering both humoral and cellular immune responses that generate antibodies and T-cell mediated immunity against H. pylori. This approach aims to prevent initial infection or reduce bacterial colonization in the stomach, thereby preventing peptic ulcer disease, chronic gastritis, and gastric cancer associated with H. pylori infection.","oneSentence":"This vaccine stimulates the immune system to recognize and eliminate Helicobacter pylori bacteria, preventing infection and associated gastric diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:50.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Helicobacter pylori infection"},{"name":"Prevention of H. pylori-associated peptic ulcer disease and gastric cancer"}]},"trialDetails":[{"nctId":"NCT04521764","phase":"PHASE1","title":"A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-09-23","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Adenocarcinoma","enrollment":54},{"nctId":"NCT05683834","phase":"PHASE1, PHASE2","title":"Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-09-22","conditions":"Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus","enrollment":25},{"nctId":"NCT04579250","phase":"PHASE1","title":"Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-08","conditions":"Influenza","enrollment":25},{"nctId":"NCT03814720","phase":"PHASE1","title":"Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-01","conditions":"Influenza Infection","enrollment":52},{"nctId":"NCT03270800","phase":"PHASE1","title":"Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers","status":"COMPLETED","sponsor":"ImevaX","startDate":"2017-01-30","conditions":"Helicobacter Pylori Infected Subjects, Helicobacter Pylori Naive Subjects","enrollment":72},{"nctId":"NCT00736476","phase":"PHASE1","title":"Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-10","conditions":"Helicobacter Pylori Infection","enrollment":63},{"nctId":"NCT02302170","phase":"PHASE3","title":"A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2004-12","conditions":"H. Pylori Infection","enrollment":4464},{"nctId":"NCT00613665","phase":"PHASE1","title":"Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2001-02","conditions":"Helicobacter Pylori, Gastritis, Gastric Cancer","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":120,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oral Recombinant Helicobacter Pylori Vaccine"],"phase":"phase_3","status":"active","brandName":"H. pylori vaccine","genericName":"H. pylori vaccine","companyName":"Jiangsu Province Centers for Disease Control and Prevention","companyId":"jiangsu-province-centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and eliminate Helicobacter pylori bacteria, preventing infection and associated gastric diseases. Used for Prevention of Helicobacter pylori infection, Prevention of H. pylori-associated peptic ulcer disease and gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}